SCHEMBL1153471

SCHEMBL1153471

Brc1ccc(-c2ccc3ccccc3c2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.65
ESR1 P03372 4/20 0.61
ESR2 Q92731 4/20 0.61
ALDH1A1 P00352 3/20 0.56
MAPK1 P28482 1/20 0.56
ALOX5 P09917 1/20 0.54
HSD17B1 P14061 1/20 0.52
HSD17B2 P37059 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
GSTP1 P09211 1/20 0.50
CYP11B1 P15538 2/20 0.48
CYP11B2 P19099 2/20 0.48
CYP17A1 P05093 1/20 0.48
CYP19A1 P11511 1/20 0.48
MAOB P27338 1/20 0.47
LPL P06858 1/20 0.46
LIPG Q9Y5X9 1/20 0.46
KDM4E B2RXH2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29772972 1.00 CYP2A6 (0.65) CYP2A6ESR1ESR2ALDH1A1MAPK1
SCHEMBL29362228 1.00 CYP2A6 (0.65) CYP2A6ESR1ESR2ALDH1A1MAPK1
SCHEMBL2518014 1.00 CYP2A6 (0.65) CYP2A6ESR1ESR2ALDH1A1MAPK1
SCHEMBL31481607 1.00 CYP2A6 (0.65) CYP2A6ESR1ESR2ALDH1A1MAPK1
SCHEMBL28527548 1.00 CYP2A6 (0.65) CYP2A6ESR1ESR2ALDH1A1MAPK1
Anthracene SCHEMBL28888145 0.98 CYP2A6 (0.62) CYP2A6ESR1ESR2ALDH1A1MAPK1
SCHEMBL25235997 0.94 CYP2A6 (0.58) CYP2A6ESR1ESR2ALDH1A1MAPK1
SCHEMBL12192925 0.93 CYP2A6 (0.77) CYP2A6ESR1ESR2ALDH1A1MAPK1
SCHEMBL28392418 0.93 CYP2A6 (0.56) CYP2A6ESR1ESR2ALDH1A1MAPK1
SCHEMBL2512052 0.91 ALDH1A1 (0.71) CYP2A6ESR1ESR2ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 722 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102516014-B Anthracene derivative with asymmetric molecular structure and its preparation method and use JILIN OLED OPTICAL AND ELECTRONIC MATERIALS CO LTD 2014-05-14 CN claimed
CN-102516014-A Anthracene derivative with asymmetric molecular structure and its preparation method and use JILIN OLED OPTICAL AND ELECTRONIC MATERIALS CO LTD 2012-06-27 CN claimed
US-12635408-B2 Organic electroluminescence device and amine compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2026-05-19 US disclosed
EP-4729506-A1 LIGHT EMITTING ELEMENT, MONOAMINE COMPOUND FOR THE LIGHT EMITTING ELEMENT, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT EMITTING ELEMENT Samsung Display Co., Ltd. (KR) 2026-04-22 EP disclosed
US-20260107630-A1 LIGHT EMITTING ELEMENT, MONOAMINE COMPOUND FOR THE LIGHT EMITTING ELEMENT, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT EMITTING ELEMENT SAMSUNG DISPLAY CO LTD (KR) 2026-04-16 US disclosed
US-12590076-B2 Compound, material for organic electroluminescent element, organic electroluminescent element, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2026-03-31 US disclosed
US-12588407-B2 Organic light-emitting element LG CHEM, LTD. (KR) 2026-03-24 US disclosed
US-12588408-B2 Light-emitting element, light-emitting device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2026-03-24 US disclosed
EP-4692058-A1 ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE Hodogaya Chemical Co., Ltd. (JP) 2026-02-11 EP disclosed
US-12532660-B2 Light emitting device and amine compound for the same SAMSUNG DISPLAY CO., LTD. (KR) 2026-01-20 US disclosed
US-12514118-B2 Heterocyclic compound, organic light emitting device comprising the same, method for manufacturing the same and composition for organic material layer of organic light emitting device LT MATERIALS CO., LTD. (KR) 2025-12-30 US disclosed
EP-1333018-A1 ORGANIC ELECTROLUMINESCENT ELEMENT IDEMITSU KOSAN CO., LTD. (JP) 2003-08-06 EP disclosed
EP-0801644-A4 POLYARYLCARBAMOYLAZA -AND- CARBAMOYLALKANEDIOIC ACIDS RHONE POULENC RORER PHARMA (US) 2001-03-07 EP disclosed
US-5712396-A PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS MAGNIN DAVID R (US) 1998-01-27 US disclosed
EP-0801644-A1 POLYARYLCARBAMOYLAZA -AND- CARBAMOYLALKANEDIOIC ACIDS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1997-10-22 EP disclosed
US-5567841-A ANTICHOLESTEROL AGENT BRISTOL-MYERS SQUIBB COMPANY (US) 1996-10-22 US disclosed
US-5556990-A SQUALENE SYNTHASE INHIBITORS, ANTICHOLESTEROL AGENTS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1996-09-17 US disclosed
WO-1996018615-A1 POLYARYLCARBAMOYLAZA -AND- CARBAMOYLALKANEDIOIC ACIDS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1996-06-20 WO disclosed
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US disclosed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12532660-B2 Light emitting device and amine compound for the same ARL1, CRY1, RFT1 CYP2A6 1173/4885ESR1 62/4885ESR2 44/4885
US-12588407-B2 Organic light-emitting element LAS1L, LEF1, ARL1 CYP2A6 2105/4885ESR1 74/4885ESR2 48/4885
US-20260107630-A1 LIGHT EMITTING ELEMENT, MONOAMINE COMPOUND FOR THE LIGHT EMITTING ELEMENT, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT EMITTING ELEMENT SLC18A1, SLC6A2, SLC18A2 CYP2A6 429/4885ESR1 137/4885ESR2 152/4885
US-12514118-B2 Heterocyclic compound, organic light emitting device comprising the same, method for manufacturing the same and composition for organic material layer of organic light emitting device C1R, CBR3, CBR1 CYP2A6 1159/4885ESR1 304/4885ESR2 287/4885
US-12635408-B2 Organic electroluminescence device and amine compound for organic electroluminescence device LEF1, MLLT1, NAP1L1 CYP2A6 3225/4885ESR1 209/4885ESR2 160/4885
US-12588408-B2 Light-emitting element, light-emitting device, electronic device, and lighting device CYBA, AHR, SUN2 CYP2A6 145/4885ESR1 5/4885ESR2 100/4885
US-12590076-B2 Compound, material for organic electroluminescent element, organic electroluminescent element, and electronic device ESR1, LEF1, AR CYP2A6 2269/4885ESR1 1/4885ESR2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.